{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Clotrimazole&page=2", "query": { "intervention": "Clotrimazole", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Clotrimazole&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T05:00:37.125Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04341402", "title": "Systemic Uptake of Diclofenac Sodium in Combination With Miconazole as Antifungal Nail Gel When Applied Daily With Monitoring of Hepatic and Renal Enzymes, and Serum Levels of Diclofenac 12 Hours After Application, and at 3 and 6 Months Study", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tinea Unguium, Onychomycosis" ], "interventions": [ { "name": "Antifungal Nail Gel Study", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "William N Handelman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "21 Years to 100 Years" }, "enrollment_count": 30, "start_date": "2020-05-01", "completion_date": "2021-05-01", "has_results": false, "last_update_posted_date": "2020-04-10", "last_synced_at": "2026-09-29T05:00:37.125Z", "location_count": 1, "location_summary": "St. Petersburg, Florida", "locations": [ { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04341402" }, { "nct_id": "NCT00526058", "title": "(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Secura then Futura", "type": "DEVICE" }, { "name": "Futura then Secura", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "B. Braun Medical Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "25 Years to 70 Years" }, "enrollment_count": 18, "start_date": "2007-08", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2018-09-14", "last_synced_at": "2026-09-29T05:00:37.125Z", "location_count": 2, "location_summary": "Hartford, Connecticut • Kansas City, Kansas", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00526058" }, { "nct_id": "NCT00004492", "title": "Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Anemia" ], "interventions": [ { "name": "clotrimazole", "type": "DRUG" }, { "name": "hydroxyurea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "1999-10", "completion_date": "2001-09", "has_results": false, "last_update_posted_date": "2015-03-25", "last_synced_at": "2026-09-29T05:00:37.125Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004492" }, { "nct_id": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Samalizumab (BAML-16-001-S1)", "type": "BIOLOGICAL" }, { "name": "BI 836858 (BAML-16-001-S2)", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Daunorubicin (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S2)", "type": "DRUG" }, { "name": "AG-221 (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Daunorubicin (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Pevonedistat (BAML-16-001-S9)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S9)", "type": "DRUG" }, { "name": "AG-120 (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "AZD5153 (BAML-16-001-S10)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S10)", "type": "DRUG" }, { "name": "TP-0903 (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "AZD5991 (BAML-16-001-S18)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S18)", "type": "DRUG" }, { "name": "SNDX-5613 (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 1)", "type": "DRUG" }, { "name": "ficlatuzumab (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S24)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 2)", "type": "DRUG" }, { "name": "Bleximenib (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Revumenib (BAML-16-001-S26/HO177)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S26/HO177)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Beat AML, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3000, "start_date": "2016-11", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-29T05:00:37.125Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013998" }, { "nct_id": "NCT03130738", "title": "Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Otomycosis" ], "interventions": [ { "name": "7-Day Miconazole Oil (Miconazole 2%)", "type": "DRUG" }, { "name": "14-Day Miconazole Oil (Miconazole 2%)", "type": "DRUG" }, { "name": "14-Day Placebo - Oil Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hill Dermaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Months", "maximum_age": null, "sex": "ALL", "summary": "25 Months and older" }, "enrollment_count": 65, "start_date": "2017-04-20", "completion_date": "2019-08-06", "has_results": true, "last_update_posted_date": "2022-10-05", "last_synced_at": "2026-09-29T05:00:37.125Z", "location_count": 6, "location_summary": "Chula Vista, California • La Jolla, California • Boynton Beach, Florida + 3 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03130738" }, { "nct_id": "NCT07215273", "title": "Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Invasive Mould Infection" ], "interventions": [ { "name": "EL219", "type": "DRUG" }, { "name": "Active Comparator- IV Antifungal (LAmB or voriconazole)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-02-13", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-09-29T05:00:37.125Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07215273" }, { "nct_id": "NCT00805090", "title": "Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Insufficiency, Chronic", "Hepatic Insufficiency", "Healthy" ], "interventions": [ { "name": "Sporanox", "type": "DRUG" }, { "name": "Diclofenac Sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Javelin Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 37, "start_date": "2008-12", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2009-04-30", "last_synced_at": "2026-09-29T05:00:37.125Z", "location_count": 3, "location_summary": "Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00805090" }, { "nct_id": "NCT04847050", "title": "A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor Malignancy", "Hematologic Malignancy", "Leukemia", "Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Messenger ribonucleic acid (mRNA)-1273 Vaccine", "type": "BIOLOGICAL" }, { "name": "Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster", "type": "BIOLOGICAL" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "Antibiotics", "type": "OTHER" }, { "name": "Anti-viral agents", "type": "OTHER" }, { "name": "Anti-fungal agent", "type": "OTHER" }, { "name": "Anti-emetics", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2021-04-28", "completion_date": "2023-05-25", "has_results": true, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-09-29T05:00:37.125Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04847050" }, { "nct_id": "NCT03226418", "title": "Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Therapy-Related Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "glasdegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 75, "start_date": "2017-07-07", "completion_date": "2024-10-01", "has_results": true, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-09-29T05:00:37.125Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03226418" }, { "nct_id": "NCT01668849", "title": "Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Oral Mucositis" ], "interventions": [ { "name": "Grape extract", "type": "DIETARY_SUPPLEMENT" }, { "name": "Lortab, Fentanyl patch, mouthwash", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "20 Years to 85 Years" }, "enrollment_count": 60, "start_date": "2012-08-02", "completion_date": "2022-06-03", "has_results": false, "last_update_posted_date": "2022-08-09", "last_synced_at": "2026-09-29T05:00:37.125Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01668849" } ] }